GILD Stock Surges 14% With A 5-day Winning Spree On Citi PT Hike To $156
Gilead Sciences (GILD) – a developer and seller of HIV/AIDS medicines – hit 5-day winning streak, with cumulative gains over this period amounting to a 14%. The company market cap has surged by about $21 Bil over the last 5 days, and currently stands at $175 Bil.
The stock has YTD (year-to-date) return of 14.9% compared to 1.9% for S&P 500. This calls for a re-evaluation of the stock’s valuation to find out whether this is an opportunity, or a trap.
What Triggered The Rally?
[1] Multiple Analyst Price Target Hikes
- Citigroup Target Raised to $156
- UBS Target Lifted To $155
- Impact: Broad-Based Institutional Buying, New 52-Week High Reached
[2] Positive Trodelvy Clinical Data
- Phase 3 Results Published
- New England Journal of Medicine Feature
- Impact: Increased Investor Confidence, Oncology Pipeline Validation
Opportunity or Trap?
Below is our take on valuation.
There are only a couple of things to fear in GILD stock given its overall Strong operating performance and financial condition. Considering stock’s Moderate valuation, we think it is Attractive (For details, see Buy or Sell GILD).
But here is the real interesting point.
You are reading about this 14% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. Our High Quality Portfolio has flagged 5 new opportunities that haven not surged yet.
Returns vs S&P 500
The following table summarizes the return for GILD stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | GILD | S&P 500 |
|---|---|---|
| 1D | 2.3% | 0.4% |
| 5D (Current Streak) | 13.6% | 2.7% |
| 1M (21D) | 12.2% | 0.7% |
| 3M (63D) | 17.3% | 2.8% |
| YTD 2026 | 14.9% | 1.9% |
| 2025 | 36.6% | 16.4% |
| 2024 | 18.7% | 23.3% |
| 2023 | -2.0% | 24.2% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 55 S&P constituents with 3 days or more of consecutive gains and 62 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 22 | 35 |
| 4D | 10 | 23 |
| 5D | 17 | 0 |
| 6D | 3 | 4 |
| 7D or more | 3 | 0 |
| Total >=3 D | 55 | 62 |
Key Financials for Gilead Sciences (GILD)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $27.1 Bil | $28.8 Bil |
| Operating Income | $8.8 Bil | $10.5 Bil |
| Net Income | $5.7 Bil | $480.0 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $7.1 Bil | $7.8 Bil |
| Operating Income | $2.7 Bil | $3.5 Bil |
| Net Income | $2.0 Bil | $3.1 Bil |
While GILD stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.